Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.5K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.5K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

145
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
145
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

223
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
223
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers.

Journal of neuroendocrinology·2026
Same author

Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance.

The Journal of clinical endocrinology and metabolism·2026
Same author

Distinct plasma protein profiles after long-term remission of Cushing's disease.

The Journal of clinical endocrinology and metabolism·2026
Same author

Unravelling mesenteric fibrosis in small intestinal neuroendocrine tumours and implications for clinical management.

Endocrine-related cancer·2026
Same author

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE: A post-authorisation safety study.

Journal of neuroendocrinology·2026
Same author

Time trends in incidence, treatment, and survival of patients with adrenocortical carcinoma, a nationwide study.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Aug 26, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Peptide Receptor Radionuclide Therapy.

Johannes Hofland1, Tessa Brabander2, Frederik A Verburg2

  • 1Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, Rotterdam, The Netherlands.

The Journal of Clinical Endocrinology and Metabolism
|October 5, 2022
PubMed
Summary

Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE offers improved survival and quality of life for patients with neuroendocrine neoplasms (NENs). This theranostic approach shows promise for various NEN types and is under investigation for first-line use.

Keywords:
177Lu-DOTATATEPRRTneuroendocrinepeptide receptor radionuclide therapytumor

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.0K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Related Experiment Videos

Last Updated: Aug 26, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.0K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmacology

Background:

  • Theranostics combines diagnostic imaging with targeted radionuclide therapy.
  • Peptide receptor radionuclide therapy (PRRT) with somatostatin analogs (SSAs) is established for somatostatin receptor-positive neuroendocrine neoplasms (NENs).
  • 177Lu-DOTATATE is approved for gastroenteropancreatic (GEP) NENs, improving progression-free survival and quality of life.

Purpose of the Study:

  • To review the role and expanding applications of PRRT with 177Lu-DOTATATE in NENs.
  • To highlight the efficacy in functioning metastatic GEP NENs and potential in other NEN types.
  • To discuss ongoing research in first-line PRRT and novel radiolabeled SSAs.

Main Methods:

  • Review of clinical data and regulatory approvals for PRRT with 177Lu-DOTATATE.
  • Analysis of treatment outcomes in various NEN subtypes.
  • Exploration of emerging theranostic agents and treatment strategies.

Main Results:

  • PRRT with 177Lu-DOTATATE significantly improves progression-free survival and quality of life in GEP NENs.
  • Positive responses observed in functioning metastatic GEP NENs (insulinomas, VIPomas, glucagonomas, gastrinomas) and carcinoid syndrome.
  • Therapy shows potential for bronchopulmonary NENs, pheochromocytomas, paragangliomas, and medullary thyroid carcinomas.

Conclusions:

  • PRRT with 177Lu-DOTATATE is a valuable theranostic treatment for NENs, with established efficacy and expanding indications.
  • Ongoing research focuses on first-line application and novel radioligands, including alpha-emitters and antagonists.
  • Theranostics represents a significant advancement in personalized cancer therapy for NENs.